Jazz Pharmaceuticals plc and Chimerix have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both companies and is expected to close in the second quarter of 2025. Diversifying Jazz Pharmaceuticals’ Oncology Portfolio Chimerix’s lead clinical asset is dordaviprone, a novel first-in-class small molecule treatment in development for H3 K2...